Policy | July 26, 2022
Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Better serving global partners and advancing healthcare innovation
Allegra-D had U.S. retail sales of approximately $45 million as of May 2022 according to IRI.
Lupin Diagnostics will equip doctors with accurate diagnosis in the patient journey by leveraging innovative technologies
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
Orion to receive an upfront payment of USD 290 million
She joins Enveda from Gilead Sciences
Dr. Reddy's Fesoterodine Fumarate Extended-Release Tablets are available in 4 mg and 8 mg Tablets, each in bottle count sizes of 30.
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
Subscribe To Our Newsletter & Stay Updated
